Literature DB >> 18759704

Safety of ceftriaxone sodium at extremes of age.

Scott V Monte1, William Allan Prescott, Kristin K Johnson, Lori Kuhman, Joseph A Paladino.   

Abstract

BACKGROUND: Isolated reports of neonatal and infant deaths associated with ceftriaxone-calcium precipitation in the lungs and kidneys have prompted a recommendation from the US FDA in June 2007 advising that in patients of all ages, calcium-containing solutions should not be administered simultaneously or within 48 h of the last ceftriaxone dose.
OBJECTIVE: To provide a comprehensive review of the literature surrounding the safety of ceftriaxone in the neonatal (< or = 28 days) and geriatric populations (> or = 65 years).
METHODS: Multi-database literature search for original research articles, review articles and case reports pertaining to safety of ceftriaxone in the neonatal and geriatric populations. RESULTS/
CONCLUSIONS: Ceftriaxone should be avoided or significantly minimized in neonates (especially those treated concomitantly with intravenous calcium solutions and those with hyperbilirubinemia), and potentially restricted in the geriatric population treated concomitantly with intravenous calcium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759704     DOI: 10.1517/14740338.7.5.515

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  16 in total

1.  Notice to Hospitals Regarding Ceftriaxone-Calcium Incompatibility: What's a Clinician to Do?

Authors:  Alfred Gin; Sandra Walker
Journal:  Can J Hosp Pharm       Date:  2009-03

2.  Evaluation of tools to prevent drug incompatibilities in paediatric and neonatal intensive care units.

Authors:  Isabella De Giorgi; Bertrand Guignard; Caroline Fonzo-Christe; Pascal Bonnabry
Journal:  Pharm World Sci       Date:  2010-06-17

Review 3.  Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.

Authors:  Young R Lee; Danni McMahan; Catherine McCall; Gregory K Perry
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

4.  The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants <60 days of Age in Malawi.

Authors:  Elizabeth M Molyneux; Queen Dube; Francis M Banda; Msandeni Chiume; Isaac Singini; Macpherson Mallewa; Edward C Schwalbe; Robert S Heyderman
Journal:  Pediatr Infect Dis J       Date:  2017-12       Impact factor: 2.129

5.  Survey of Canadian Pharmacists' Responses to Warnings of Potential Interactions Between Ceftriaxone and Calcium in IV Solutions.

Authors:  Curtis K Harder; John J Hawboldt
Journal:  Can J Hosp Pharm       Date:  2009-11

6.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

7.  Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice.

Authors:  John S Esterly; Emily Steadman; Marc H Scheetz
Journal:  Int J Clin Pharm       Date:  2011-03-29

Review 8.  Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature.

Authors:  Patrick C Donnelly; Rebecca M Sutich; Ryan Easton; Oluwatunmise A Adejumo; Todd A Lee; Latania K Logan
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

9.  Evaluation of a potential clinical interaction between ceftriaxone and calcium.

Authors:  Emily Steadman; Dennis W Raisch; Charles L Bennett; John S Esterly; Tischa Becker; Michael Postelnick; June M McKoy; Steve Trifilio; Paul R Yarnold; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 10.  Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.

Authors:  Yohannes Hagos; Natascha A Wolff
Journal:  Toxins (Basel)       Date:  2010-08-09       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.